APA (7th ed.) Citation

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., . . . Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. The lancet oncology, 13(3), 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0

Chicago Style (17th ed.) Citation

Ciuleanu, Tudor, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, and Emilio Esteban Gonzalez. "Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-line Treatment of Patients with Advanced, Non-small-cell Lung Cancer with Poor Prognosis (TITAN): A Randomised Multicentre, Open-label, Phase 3 Study." The Lancet Oncology 13, no. 3 (2012): 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0.

MLA (9th ed.) Citation

Ciuleanu, Tudor, et al. "Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-line Treatment of Patients with Advanced, Non-small-cell Lung Cancer with Poor Prognosis (TITAN): A Randomised Multicentre, Open-label, Phase 3 Study." The Lancet Oncology, vol. 13, no. 3, 2012, pp. 300-308, https://doi.org/10.1016/S1470-2045(11)70385-0.